Interventional Oncology Devices Market Size, Share & Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Other Cancers), By Product Type (Ablation Devices, Embolization Devices, Supporting Devices, Next-Generation Devices), By End-User (Hospitals, Ambulatory Surgery Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Interventional Oncology Devices Market Size

The global interventional oncology devices market size was valued at USD 2.68 billion in 2025 and is projected to grow from USD 2.95 billion in 2026 to USD 6.39 billion by 2034, registering a CAGR of 10.13% during the forecast period from 2026 to 2034. North America dominated the interventional oncology devices market with a market share of 39.2% in 2025.

A branch of interventional radiology called interventional oncology (IO) employs imaging-guided minimally invasive treatments to diagnose and treat cancer and disorders connected to it. A minimally invasive tumor biopsy can be performed safely by interventional oncologists to obtain the necessary genetic or proteomic data for precisely customizing the chemotherapeutic drugs anticipated to have the desired therapeutic impact. Interventional oncology devices diagnose and treat cancer with minimally invasive procedures and modern imaging technology.

Advanced oncology's interventional oncology specialty treats solid tumors in the liver, kidneys, lungs, bones, and other organs by using X-rays, ultrasounds, computed tomography (CT), or magnetic resonance imaging (MRI) to guide tiny instruments (biopsy needles, ablation electrodes, intravascular catheters). Interventional oncology techniques mainly fall into two categories: diagnostic treatments that help identify suspicious neoplasms on tissue and therapeutic approaches that treat or lessen tumors. These techniques have the benefit of having a far lesser effect on the body as a whole and the organ being treated. Also, it offers a quicker recovery period compared to conventional open procedures.

Cancer Type Insight

The global interventional oncology devices market is divided into liver cancer, lung cancer, kidney cancer, prostate cancer, and other cancers.The sub-orbital reusable launch vehicles segment is responsible for the largest market share and is anticipated to exhibit a CAGR of 12.01% over the forecast period. According to the Global Cancer Observatory, the estimated number of liver cancer in 2020 was 906,000 and is expected to reach 1.40 million in 2040. The highest share of the liver cancer segment can be attributed to the increased consumption of alcohol, chronic viral hepatitis, liver cirrhosis, and a rise in the obesity index globally. Moreover, liver cancer is less common in the U.S. than in sub-Saharan Africa and South Asian countries. Liver cancer accounts for more than 70,000 deaths each year.

According to the Global Cancer Observatory, the estimated number of lung cancer in 2020 was 2.21 million and is expected to reach 3.63 million in 2040. Active and passive cigarette smoking is the major risk factor for lung cancer, and rising air pollution leads to a high growth rate of this segment during the forecast period. According to the Centers for Disease Control and Prevention (CDC), people who smoke are 15 to 30 times more prone to be diagnosed with lung cancer than those who do not smoke.

Request Customizationto receive a tailored report.

Product Type Insight

The ablation devices segment dominates the global market and is projected to exhibit a CAGR of 11.86% over the forecast period. Tumor ablation is a minimally invasive technique for treating liver, kidney, and lung cancers. The tumor ablation procedure involves using thermal energy to heat or cool tissue to cytotoxic levels, i.e., less than -40ºC or more than 60ºC. Ablation is used as the first line of treatment in a few cases of hepatocellular carcinoma. It is also considered an important option for patients who are either not eligible for surgery or have failed chemotherapy. Ablation is generally used for tumors less than 3cm; for tumors of larger size (3-5 cm), ablation may be used along with embolization.

Tumor embolization is a minimally invasive procedure in which thin catheters are guided into the arteries providing the blood supply to the tumor to stop the blood supply to the tumor or deliver substances to kill the tumor. Embolization procedures are also used in patients for which surgery is not an option. It can also be utilized on patients with large tumors for whom ablation is not an option. The embolization procedures act by occluding the blood supply to the tumor, thereby producing ischemia in the tumors, resulting in tumor necrosis.

End-User Insight

The government segment owns the highest market share and is estimated to exhibit a CAGR of 11.91% during the forecast period. Hospitals are at the forefront in terms of interventional oncology device adoption. The increasing focus on evidence-based care has been among the strongest drivers for adopting interventional oncology. The adoption of interventional oncology devices in private and public hospitals has continuously increased. In addition, various hospitals in developed and emerging economies have established specialized subdivisions for interventional oncology. Another major driving factor for the segment's growth is the increase in minimally invasive hospital surgeries.

The growing prominence of outpatient surgeries and the rising establishment of ASCs are the leading factors promoting the market's growth for global interventional oncology devices. The adoption of interventional oncology devices in ambulatory surgical centers can be boosted by prioritizing the increasing demand for minimally invasive surgeries that are easier to implement. Some major drivers for adopting interventional oncology in ASCs include personalized patient care and reduced recovery time.

Speak to an Analystto discuss market opportunities.

Regional Analysis

Based on region, the global interventional oncology devices market is bifurcated into North America, Europe, Asia-Pacific, and Rest-of-the-World. North America is the most significant global interventional oncology devices market shareholder and is anticipated to exhibit a CAGR of 11.35% during the forecast period. The highest market share of the North American interventional oncology devices market can be attributed to the high prevalence of cancer, the growing geriatric population, the high preference for minimally invasive devices, and high reimbursement rates. According to Global Cancer Observatory, 37,948 cases of liver cancer were recorded in the U.S. in 2018; this number is expected to increase by up to 4,193 by 2025. Additionally, the U.S. accounts for 90% of cases of liver cancer across North America. According to National Cancer Institute, there were approximately 15.5 million cancer survivors in the U.S. in the year 2016, and this number is expected to rise to 20.3 million by 2026. In addition, the United States Food and Drug Administration (USFDA) and Health Canada are the central regulatory authorities in the North American region. These authorities govern the classification and set rules and guidelines for medical devices, including interventional oncology devices.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe is estimated to exhibit a CAGR of 12.61% over the forecast period. The major driving factors for cancer in Europe include the availability of good medical facilities, preference for interventional procedures by European people, high consumption of alcohol, and high preference and incidence of cancer. According to the global cancer observatory, 4,229,662 new cancer cases were observed in 2018, of which 2,247,518 were males and 1,982,144 were females. Moreover, breast, colorectum, lung, and prostate cancer are the most prevalent cancer types in the region. European Commission funds various research programs to augment the fight against cancer. One such program is Horizon 2020. The European Union (EU) led the program for research and innovation in cancer, which started in 2014. Approximately 980 projects have been funded for USD 1.4 billion (1.2 billion Euros). The government's funding and research programs are expected to drive the Europe interventional oncology devices market during the forecast period.

The Asia-Pacific interventional oncology devices market is one of the lucrative markets with immense potential for expansion by key players of the global interventional oncology market. The Asia-Pacific interventional oncology devices market is expected to grow the fastest during the forecast period. This can be attributed to the massive geriatric population base, demand for minimally invasive and non-invasive surgical procedures, and high cancer prevalence rates. In addition, the growing prevalence of cancer in the geriatric population and the successful adoption of non-invasive devices for cancer treatment have significantly enhanced the scope of interventional oncology devices and promoted its growth in the region.

Further, Asia-Pacific represents a diverse market where synergies can easily be leveraged through unique and distinct market developmental strategies. Each region's market has different distribution systems, regulations, registration, financing mechanisms, and customer behavior. The availability of developed and developing markets in the same region has facilitated the growth of the interventional oncology devices market.

The Rest-of-the-World constitutes Latin America, the Middle East and Africa, the Caribbean, and Oceania regions. The anticipated growth is attributed to the rise in the prevalence of different types of cancer and the growing prominence of non-invasive diagnostics. Further, several programs, such as the African Health Initiative implemented by government bodies to expand the accessibility of healthcare facilities, are promoting the growth of the interventional oncology devices market in the region. However, the need for trained and certified medical oncologists and favorable reimbursement policies restrain the market growth in the region.

List of Key and Emerging Players in Interventional Oncology Devices Market